Status:
TERMINATED
ALY688-SR in Generally Healthy Overweight or Obese Adults
Lead Sponsor:
Allysta Pharmaceutical
Collaborating Sponsors:
INC Research Australia Pty Ltd
Conditions:
Overweight and Obesity
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
First in human study of ALY688-SR administered as a subcutaneous injection
Detailed Description
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ALY688-SR compared to placebo administered as a subcutaneous injection.
Eligibility Criteria
Inclusion
- Body mass index 24 to 35 kg/m2 Body weight 60 to 120 kg,
Exclusion
- Confirmed diabetes on treatment Inadequately managed hypertension Poorly controlled hypercholesterolemia
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04855565
Start Date
May 19 2021
End Date
August 3 2021
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network
Melbourne, Victoria, Australia, 3004